Study Protocol

Published on 10 Feb 2023

Protocol for pyrotinib cardiac safety in patients with HER2-positive early or locally advanced breast cancer–The EARLY-MYO-BC study

in Cardio-Oncology

Yezi Chai
Meng Jiang
Yaohui Wang
Qiming Liu
Qifan Lu
Zhengyu Tao
Qizhen Wu
Wenjin Yin
Jinsong Lu
Jun Pu

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2023.1021937

2,572 views
2 citations

Case Report

Published on 09 Feb 2023

Case report: The diagnostic challenge of primary cardiac intimal sarcoma

in Cardio-Oncology

Naili Ye
Lan Lan
Huijuan Hu
Jinping Liu
Haibo Xu

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2023.1089636

2,374 views
4 citations

Original Research

Published on 08 Feb 2023

Artificial intelligence-augmented analysis of contemporary procedural, mortality, and cost trends in carcinoid heart disease in a large national cohort with a focus on the “forgotten pulmonic valve”

in Cardio-Oncology

Dominique J. Monlezun
Andrew Badalamenti
Awad Javaid
Kostas Marmagkiolis
Kevin Honan
Jin Wan Kim
Rishi Patel
Bindu Akhanti
Dan Halperin
Arvind Dasari

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2022.1071138

4,648 views
3 citations

Case Report

Published on 08 Feb 2023

Case report: Persistent ST-segment elevation due to cardiac metastasis from lung cancer

in Cardio-Oncology

Jiawei Zhou
Chengchuang Zhan
Jing Zhou
Chao Wei
Cao Zou

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2023.1001527

1,815 views
3 citations

Original Research

Published on 07 Feb 2023

In-hospital and one-year outcomes in cancer patients receiving percutaneous coronary intervention for acute myocardial infarction: A real-world study

in Cardio-Oncology

Manyun Tang
Yidan Wang
Xiangqi Cao
John D. Day
Hui Liu
Chaofeng Sun
Guoliang Li

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2022.1005473

2,027 views

Original Research

Published on 07 Feb 2023

Five-year cardiovascular outcomes in patients with chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib: A cohort study using data from a large multinational collaborative network

in Cardio-Oncology

Rafael Amorim Belo Nunes
Precil Diego Miranda de Menezes Neves
Leandro Menezes Alves da Costa
Philip Bachour
Marcelo José de Carvalho Cantarelli
Gustavo Bernardes de Figueiredo Oliveira
Álvaro Avezum Jr.

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2023.888366

4,665 views

Editorial

Published on 01 Feb 2023

Editorial: HF2Cancer: Exploring bidirectional interaction between cardiovascular diseases and cancer

in Cardio-Oncology

Canan G. Nebigil
Michael W. Y. Chan

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2023.1145780

929 views

Original Research

Published on 25 Jan 2023

Higher risk of cardiovascular mortality than cancer mortality among long-term cancer survivors

in Cardio-Oncology

Zhipeng Wang
Zeyu Fan
Lei Yang
Lifang Liu
Chao Sheng
Fengju Song
Yubei Huang
Kexin Chen

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2023.1014400

4,033 views
15 citations

Original Research

Published on 24 Jan 2023

Evaluation of contemporary echocardiographic and histomorphology parameters in predicting mortality in patients with endomyocardial biopsy-proven cardiac AL amyloidosis

in Cardio-Oncology

Efstratios Koutroumpakis
Adam Niku
Christopher K. Black
Abdelrahman Ali
Humaira Sadaf
Juhee Song
Nicolas Palaskas
Cezar Iliescu
Jean-Bernard Durand
Syed Wamique Yusuf

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2022.1073804

1,479 views
4 citations

Original Research

Published on 23 Jan 2023

Incidence of adverse cardiovascular events associated with immune checkpoint inhibitors and risk factors for left ventricular dysfunction: A single-center prospective clinical study

in Cardio-Oncology

Chuan Zhang
Zhulu Chen
Shu Qin
Yuxi Zhu
Linjie Shu
Zhong Zuo

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2023.1052699

2,403 views
7 citations

Correction

Published on 19 Jan 2023

Corrigendum: Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways

in Cardio-Oncology

Vincenzo Quagliariello
Margherita Passariello
Annabella Di Mauro
Ciro Cipullo
Andrea Paccone
Antonio Barbieri
Giuseppe Palma
Antonio Luciano
Simona Buccolo
Irma Bisceglia

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2023.1129873

1,033 views
2 citations

Original Research

Published on 19 Jan 2023

Risk factors from Framingham risk score for anthracyclines cardiotoxicity in breast cancer: A systematic review and meta-analysis

in Cardio-Oncology

Hao Jin
Jianfeng Xu
Zheng Sui
Lili Wang

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2023.1101585

2,603 views
3 citations

Original Research

Published on 12 Jan 2023

Association between radiotherapy and risk of death from cardiovascular diseases in lung and bronchus cancer

in Cardio-Oncology

Zhong Yi
Yu Zhang
Yu Wang
Yun Gao
Yanhong Wang
Xiangnan Li
Songwei Ru
Na Guo
Jingxuan Qiu
Meng Zhang

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2022.1068957

1,950 views
2 citations

Original Research

Published on 12 Jan 2023

Bioprosthetic valve monitoring in patients with carcinoid heart disease

in Cardio-Oncology

Kevin A. Honan
Saamir Hassan
Anita Deswal
Joerg Herrmann
Juhee Song
Dominique Monlezun
Daniel Halperin
Armeen Mahvash
Arvind Dasari
Efstratios Koutroumpakis

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2022.1072890

2,316 views
2 citations

Original Research

Published on 12 Jan 2023

Traditional risk factors and cancer-related factors associated with cardiovascular disease risk in head and neck cancer patients

in Cardio-Oncology

Amrita Mukherjee
Howard W. Wiener
Russell L. Griffin
Carrie Lenneman
Arka Chatterjee
Lisle M. Nabell
Cora E. Lewis
Sadeep Shrestha

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2022.1024846

2,663 views
7 citations

Original Research

Published on 11 Jan 2023

Identification of novel biomarkers involved in doxorubicin-induced acute and chronic cardiotoxicity, respectively, by integrated bioinformatics

in Cardio-Oncology

Hongyan Qian
Yi Qian
Yi Liu
Jiaxin Cao
Yuhang Wang
Aihua Yang
Wenjing Zhao
Yingnan Lu
Huanxin Liu
Weizhong Zhu

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2022.996809

5,456 views
3 citations

Navigation group

Articles

Protocol for pyrotinib cardiac safety in patients with HER2-positive early or locally advanced breast cancer–The EARLY-MYO-BC study

Case report: The diagnostic challenge of primary cardiac intimal sarcoma

Artificial intelligence-augmented analysis of contemporary procedural, mortality, and cost trends in carcinoid heart disease in a large national cohort with a focus on the “forgotten pulmonic valve”

Case report: Persistent ST-segment elevation due to cardiac metastasis from lung cancer

In-hospital and one-year outcomes in cancer patients receiving percutaneous coronary intervention for acute myocardial infarction: A real-world study

Five-year cardiovascular outcomes in patients with chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib: A cohort study using data from a large multinational collaborative network

Editorial: HF2Cancer: Exploring bidirectional interaction between cardiovascular diseases and cancer

Higher risk of cardiovascular mortality than cancer mortality among long-term cancer survivors

Evaluation of contemporary echocardiographic and histomorphology parameters in predicting mortality in patients with endomyocardial biopsy-proven cardiac AL amyloidosis

Incidence of adverse cardiovascular events associated with immune checkpoint inhibitors and risk factors for left ventricular dysfunction: A single-center prospective clinical study

Corrigendum: Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways

Risk factors from Framingham risk score for anthracyclines cardiotoxicity in breast cancer: A systematic review and meta-analysis

Association between radiotherapy and risk of death from cardiovascular diseases in lung and bronchus cancer

Bioprosthetic valve monitoring in patients with carcinoid heart disease

Traditional risk factors and cancer-related factors associated with cardiovascular disease risk in head and neck cancer patients

Identification of novel biomarkers involved in doxorubicin-induced acute and chronic cardiotoxicity, respectively, by integrated bioinformatics